<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "http://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<processing-meta>
<custom-meta-group content-type="composition">
<custom-meta specific-use="newgen" xlink:href="https://www.newgen.co/">
<meta-name>Composition Vendor</meta-name>
<meta-value>Newgen KnowledgeWorks (P) Ltd.</meta-value>
</custom-meta>
</custom-meta-group>
</processing-meta>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLOS Ment Health</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosmenthealth</journal-id>
<journal-title-group>
<journal-title>PLOS Mental Health</journal-title>
</journal-title-group>
<issn pub-type="epub">2837-8156</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706</article-id>
<article-id pub-id-type="publisher-id">PMEN-D-25-00524</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Mental health therapies</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Alcoholism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Alcoholism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Substance-related disorders</subject><subj-group><subject>Alcoholism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Substance-related disorders</subject><subj-group><subject>Alcoholism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Mood disorders</subject><subj-group><subject>Depression</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug therapy</subject><subj-group><subject>Neurological drug therapy</subject><subj-group><subject>Anti-addiction drug therapy</subject><subj-group><subject>Nicotine replacement therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Drug addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Drug addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Substance-related disorders</subject><subj-group><subject>Drug addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Substance-related disorders</subject><subj-group><subject>Drug addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Schizophrenia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject></subj-group></subj-group></article-categories>
<title-group>
<article-title>Alcohol and substance-induced disorder treatment cases in mental health and addiction treatment facilities from 2013 to 2022: A descriptive study</article-title>
<alt-title alt-title-type="running-head">Substance-Induced Disorder Treatment Cases</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3269-5324</contrib-id>
<name name-style="western">
<surname>Ware</surname>
<given-names>Orrin D.</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
<role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
<role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="corresp" rid="cor001">*</xref>
<xref ref-type="aff" rid="aff001"/></contrib>
</contrib-group>
<aff id="aff001"><institution-wrap><institution content-type="institution">School of Social Work, University of North Carolina at Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <state>North Carolina</state>, <country country="us">United States of America</country></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Montague-Cardoso</surname>
<given-names>Karli</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><institution-wrap><institution content-type="institution">PLOS: Public Library of Science</institution></institution-wrap>, <country country="gb">UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND</country></aff>
<author-notes>
<corresp id="cor001">* E-mail: <email xlink:type="simple">oware@unc.edu</email></corresp>
<fn fn-type="conflict" id="coi001">
<p>The author has declared that no competing interests exist.</p>
</fn>
</author-notes>
<pub-date pub-type="epub"><day>2</day><month>9</month><year>2026</year></pub-date>
<pub-date pub-type="collection"><year>2026</year></pub-date>
<volume>3</volume>
<issue>9</issue>
<elocation-id>e0000706</elocation-id>
<history>
<date date-type="received"><day>14</day><month>11</month><year>2025</year></date>
<date date-type="accepted"><day>10</day><month>8</month><year>2026</year></date>
</history>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Orrin D. Ware</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pmen.0000706"/>
<abstract>
<p>Substance use disorders may arise when individuals use substances to cope with adverse mental health symptoms. Conversely, mental health symptoms can develop because of substance use, a category of conditions called substance-induced disorders. This study used two United States-based datasets, the Mental Health Client-Level Data and the Treatment Episode Data Set Admissions, to summarize the number of cases with “alcohol-induced disorders” and “substance-induced disorders” from both mental health and substance use disorder treatment programs from 2013 to 2022. The primary study aim was to identify the percentage of cases with alcohol-induced disorders or substance-induced disorders in these treatment settings. Among all mental health disorder treatment cases, those with an alcohol or substance-induced disorder totaled N = 439,932, making up 0.7% of total cases over the analytic period. During the same period, alcohol or substance-induced disorders totaled N = 459,817, accounting for approximately 2.7% of all substance use disorder treatment cases. The majority (79%) of cases with an alcohol-induced disorder in substance use disorder treatment were identified as reporting alcohol use, with 68% having alcohol listed as their primary substance. Heroin and other opiates and synthetics accounted for the primary substance among 28.8% of cases with a substance-induced disorder in the substance use disorder treatment data. Approximately 1 in 3 cases with an alcohol-induced disorder and 1 in 4 cases with a substance-induced disorder had a depressive disorder diagnosis in mental health treatment. When considering the primary diagnosis, approximately 1 in 4 cases with an alcohol-induced disorder and 15% of cases with a substance-induced disorder had a depressive disorder as the primary diagnosis in mental health treatment. Substance-induced disorders are a significant public health concern, and more research is needed to better understand the clinical needs of this population.</p>
</abstract>
<funding-group>
<funding-statement>The author received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="1"/>
<page-count count="14"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>This study used the Substance Abuse and Mental Health Services Administration’s Mental Health Client-Level Data and the Treatment Episode Data Set Admissions. Both datasets are de-identified and publicly available. The datasets may be found using these links: [1] <ext-link ext-link-type="uri" xlink:href="https://www.samhsa.gov/data/data-we-collect/mh-cld-mental-health-client-level-data/datafiles" xlink:type="simple">https://www.samhsa.gov/data/data-we-collect/mh-cld-mental-health-client-level-data/datafiles</ext-link> and [2] <ext-link ext-link-type="uri" xlink:href="https://www.samhsa.gov/data/data-we-collect/teds-treatment-episode-data-set" xlink:type="simple">https://www.samhsa.gov/data/data-we-collect/teds-treatment-episode-data-set</ext-link>. Certain geographic locations might be restricted from accessing the dataset.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Substance-induced disorders are a category of conditions caused by substance use [<xref ref-type="bibr" rid="pmen.0000706.ref001">1</xref>]. Examples include intoxication, withdrawal, and mental health issues [<xref ref-type="bibr" rid="pmen.0000706.ref001">1</xref>]. For instance, substance-induced depressive disorder occurs when substance use triggers depressive symptoms that meet the criteria for a depressive disorder [<xref ref-type="bibr" rid="pmen.0000706.ref002">2</xref>–<xref ref-type="bibr" rid="pmen.0000706.ref004">4</xref>]. Mental health symptoms resulting from substance-induced disorders are particularly unique, as clinicians must address both the emerging psychological issues and the underlying substance use. For example, in the management of substance-induced psychosis, it is recommended that the treatment address the symptoms of psychosis and the substance(s) of concern [<xref ref-type="bibr" rid="pmen.0000706.ref005">5</xref>–<xref ref-type="bibr" rid="pmen.0000706.ref012">12</xref>].</p>
<p>Facilities that treat mental health or substance use disorders may encounter patients with substance-induced disorders. This occurs because these conditions can show symptoms of both mental health and substance use disorders. However, the literature lacks descriptive studies on substance-induced disorder cases in both mental health and substance use disorder treatment settings. Data on substance-induced disorder comorbidities, such as mental health and substance use disorders, are also lacking. Descriptive studies are important to the research literature as they can highlight the prevalence of specific conditions and who is affected by them [<xref ref-type="bibr" rid="pmen.0000706.ref013">13</xref>,<xref ref-type="bibr" rid="pmen.0000706.ref014">14</xref>]. A study analyzing the Substance Abuse and Mental Health Services Administration’s Treatment Episode Data Set Admissions [<xref ref-type="bibr" rid="pmen.0000706.ref015">15</xref>], reviewed all cases identified as having a “substance-induced disorder” from 1992 to 2022 [<xref ref-type="bibr" rid="pmen.0000706.ref016">16</xref>]. However, the study excluded cases with an “alcohol-induced disorder” except where trends of these diagnoses were examined [<xref ref-type="bibr" rid="pmen.0000706.ref016">16</xref>]. Given this, a study describing cases of “alcohol-induced disorder” in the substance use disorder treatment setting is needed. Additionally, no study has examined national data on alcohol or substance-induced disorders in the mental health treatment setting alongside substance use disorder cases in the United States. Building on Fedotov and Shustov’s previous work [<xref ref-type="bibr" rid="pmen.0000706.ref016">16</xref>], this study described instances of “alcohol-induced disorders” and “substance-induced disorders” using national treatment data from both mental health and substance use disorder programs in the United States. This study also examines mental health diagnoses reported in those receiving mental health treatment. Further, it assesses substances used among individuals with an alcohol or substance-induced disorder between 2013 and 2022. Three aims guided this research study: [a] Identify the percentage of cases identified as having alcohol-induced disorders or substance-induced disorders in mental health and substance use disorder treatment settings, [b.] Examine the prevalence of other mental health diagnoses, such as anxiety and depressive disorders, among cases with alcohol-induced disorders or substance-induced disorders in mental health treatment, and [c.] Examine the prevalence of substances used, such as alcohol and cannabis, among cases with alcohol-induced disorders or substance-induced disorders in mental health treatment.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Ethics statement</title>
<p>The University of North Carolina at Chapel Hill Institutional Review Board determined that this study does not meet the criteria for human subjects research. Further, participant consent is not applicable to this study.</p>
</sec>
<sec id="sec004">
<title>Data</title>
<p>This study utilized the Mental Health Client-Level Data [<xref ref-type="bibr" rid="pmen.0000706.ref017">17</xref>] and the Treatment Episode Data Set Admissions [<xref ref-type="bibr" rid="pmen.0000706.ref015">15</xref>]. Both are publicly available datasets provided by the Substance Abuse and Mental Health Services Administration. The Mental Health Client-Level Data includes records of individuals who received mental health treatment in the United States at facilities reporting their data to a state or other jurisdictional government [<xref ref-type="bibr" rid="pmen.0000706.ref017">17</xref>]. The Treatment Episode Data Set Admissions contains records of treatment episodes for substance use disorder treatment admissions from facilities that receive public funding [<xref ref-type="bibr" rid="pmen.0000706.ref015">15</xref>]. Both datasets are de-identified and offer annual cross-sectional data. The earliest year of available data for the Mental Health Client-Level Data is 2013; therefore, the analytic period for this study spans from 2013 to 2022.</p>
</sec>
<sec id="sec005">
<title>Sample selection</title>
<p>The Mental Health Client-Level Data and the Treatment Episode Data Set Admissions both include a variable that indicates whether a case has an “alcohol-induced disorder” or a “substance-induced disorder.” The variable in the Mental Health Client-Level Data is “SUB”. The variable in the Treatment Episode Data Set Admissions is “DSMCRIT.” These values are mutually exclusive, meaning a case can only have one of these two disorders listed in the dataset. All cases with either an “alcohol-induced disorder” or a “substance-induced disorder” from both datasets were selected and included in this current study. This resulted in N = 439,932 cases from the Mental Health Client-Level Data (2013–2022) and N = 459,817 cases from the Treatment Episode Data Set Admissions (2013–2022). Although substance-induced disorders can be diagnostically defined as conditions caused by the use of substances, including alcohol, since both datasets have values for “alcohol-induced disorder” and “substance-induced disorder,” both categories were separately examined in this study.</p>
</sec>
<sec id="sec006">
<title>Analysis</title>
<p>This descriptive study used univariable statistics to analyze demographic characteristics such as age, gender, and race/ethnicity among cases in both datasets. Annual counts of alcohol-induced disorder cases, substance-induced disorder cases, and total alcohol or substance-induced disorder cases across both datasets were examined. Since the Mental Health Client-Level Data focuses on mental health treatment, it includes a variable that identifies the primary mental health disorder. Similarly, the Treatment Episode Data Set Admissions, which centers on substance use disorder treatment, contains a variable that identifies the primary substance used. Accordingly, the percentages of primary mental health disorders were analyzed for mental health treatment cases, and the percentages of primary substances were examined for substance use disorder treatment cases. In addition to primary mental health disorders and primary substances, mental health disorders and substances used, as described in the respective datasets, were also examined. Up to three mental health disorders and substances used can be reported for each case in the Mental Health Client-Level Data and Treatment Episode Data Set Admissions, respectively. Therefore, while cases may have a listed primary mental health disorder or primary substance, secondary or tertiary substances may also be present. This study used IBM SPSS Version 31 [<xref ref-type="bibr" rid="pmen.0000706.ref018">18</xref>] and R Version 4.5.1 [<xref ref-type="bibr" rid="pmen.0000706.ref019">19</xref>], with ggplot2 to create figures [<xref ref-type="bibr" rid="pmen.0000706.ref020">20</xref>].</p>
</sec>
</sec>
<sec id="sec007" sec-type="results">
<title>Results</title>
<sec id="sec008">
<title>Mental health and substance use disorder treatment cases</title>
<p>Combining the total 2013–2022 Mental Health Client-Level Data, including cases without an alcohol or substance-induced disorder, resulted in 61,589,330 cases. Alcohol-induced disorder cases accounted for 0.2% and substance-induced disorder cases for 0.5% of the total combined mental health treatment data. Similarly, combining the total 2013–2022 Treatment Episode Data Set Admissions data, including cases without an alcohol or substance-induced disorder, resulted in 17,445,707 cases. Alcohol-induced disorder cases accounted for 0.6% and substance-induced disorder cases for 2.1% of the total combined substance use disorder treatment data. <xref ref-type="fig" rid="pmen.0000706.g001">Fig 1</xref> provides the annual percentage of cases with an alcohol or substance-induced disorder across all cases in the mental health and substance use treatment datasets.</p>
<fig id="pmen.0000706.g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmen.0000706.g001</object-id><label>Fig 1</label><caption><title>Alcohol/Substance-Induced Disorder Treatment Percentages in Addiction and Mental Health Treatment 2013 to 2022.</title></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.g001" xlink:type="simple"/></fig>
<p>The mental health treatment data of selected alcohol or substance-induced disorder cases included N = 439,932 cases, with n = 111,720 (25.4%) alcohol-induced disorder cases and 328,212 (74.6%) substance-induced disorder cases. The addiction treatment admission data of selected alcohol or substance-induced disorder cases included N = 459,817 cases, with n = 100,331 (21.8%) alcohol-induced disorder cases and 359,486 (78.2%) substance-induced disorder cases. Demographic characteristics such as age, gender, and race and ethnicity may be found in <xref ref-type="table" rid="pmen.0000706.t001">Table 1</xref>.</p>
<table-wrap id="pmen.0000706.t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmen.0000706.t001</object-id><label>Table 1</label><caption><title>Characteristics of Addiction and Mental Health Treatment Cases with Substance-Induced Disorders.</title></caption>
<alternatives><graphic id="pmen.0000706.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.t001" xlink:type="simple"/><table><colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="5">Addiction Treatment Admissions; N = 459,817</th>
</tr>
<tr>
<th align="left"/>
<th align="left" colspan="2">Alcohol-Induced Disorders; n = 100,331<break/><break/></th>
<th align="left" colspan="2">Substance-Induced Disorders; n = 359,486<break/><break/></th>
</tr>
<tr>
<th align="left">Demographics</th>
<th align="left">n</th>
<th align="left">%</th>
<th align="left">n</th>
<th align="left">%</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Age</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">12 to 17 Years Old</td>
<td align="left">3,246</td>
<td align="left">3.2%</td>
<td align="left">13,043</td>
<td align="left">3.6%</td>
</tr>
<tr>
<td align="left">18 to 29 Years Old</td>
<td align="left">23,601</td>
<td align="left">23.5%</td>
<td align="left">121,288</td>
<td align="left">33.7%</td>
</tr>
<tr>
<td align="left">30 to 39 Years Old</td>
<td align="left">26,517</td>
<td align="left">26.4%</td>
<td align="left">112,565</td>
<td align="left">31.3%</td>
</tr>
<tr>
<td align="left">40 to 49 Years Old</td>
<td align="left">21,155</td>
<td align="left">21.1%</td>
<td align="left">62,841</td>
<td align="left">17.5%</td>
</tr>
<tr>
<td align="left">50 Years and Older</td>
<td align="left">25,812</td>
<td align="left">25.7%</td>
<td align="left">49,749</td>
<td align="left">13.8%</td>
</tr>
<tr>
<td align="left"><bold>Gender</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Female</td>
<td align="left">32,412</td>
<td align="left">32.3%</td>
<td align="left">130,546</td>
<td align="left">36.3%</td>
</tr>
<tr>
<td align="left">Male</td>
<td align="left">67,881</td>
<td align="left">67.7%</td>
<td align="left">228,667</td>
<td align="left">63.6%</td>
</tr>
<tr>
<td align="left">Missing</td>
<td align="left">38</td>
<td align="left">0.0%</td>
<td align="left">273</td>
<td align="left">0.1%</td>
</tr>
<tr>
<td align="left"><bold>Race and Ethnicity</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Black or African American</td>
<td align="left">21,907</td>
<td align="left">21.8%</td>
<td align="left">59,362</td>
<td align="left">16.5%</td>
</tr>
<tr>
<td align="left">Hispanic of Any Race</td>
<td align="left">7,329</td>
<td align="left">7.3%</td>
<td align="left">42,961</td>
<td align="left">12.0%</td>
</tr>
<tr>
<td align="left">White</td>
<td align="left">56,680</td>
<td align="left">56.5%</td>
<td align="left">206,265</td>
<td align="left">57.4%</td>
</tr>
<tr>
<td align="left">Another Race</td>
<td align="left">6,132</td>
<td align="left">6.1%</td>
<td align="left">14,406</td>
<td align="left">4.0%</td>
</tr>
<tr>
<td align="left">Missing</td>
<td align="left">8,283</td>
<td align="left">8.3%</td>
<td align="left">36,492</td>
<td align="left">10.2%</td>
</tr>
<tr>
<td align="left" colspan="5"><bold>Mental Health Treatment Cases; N = 439,932</bold></td>
</tr>
<tr>
<td align="left"/>
<td align="left" colspan="2"><bold>Alcohol-Induced Disorders; n = 111,720</bold></td>
<td align="left" colspan="2"><bold>Substance-Induced Disorders; n = 328,212</bold></td>
</tr>
<tr>
<td align="left"><bold>Demographics</bold></td>
<td align="left"><bold>n</bold></td>
<td align="left"><bold>%</bold></td>
<td align="left"><bold>n</bold></td>
<td align="left"><bold>%</bold></td>
</tr>
<tr>
<td align="left"><bold>Age</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">0 to 17 Years Old</td>
<td align="left">2,822</td>
<td align="left">2.5%</td>
<td align="left">18,490</td>
<td align="left">5.6%</td>
</tr>
<tr>
<td align="left">18 to 29 Years Old</td>
<td align="left">18,876</td>
<td align="left">16.9%</td>
<td align="left">99,656</td>
<td align="left">30.4%</td>
</tr>
<tr>
<td align="left">30 to 39 Years Old</td>
<td align="left">24,365</td>
<td align="left">21.8%</td>
<td align="left">95,267</td>
<td align="left">29.1%</td>
</tr>
<tr>
<td align="left">40 to 49 Years Old</td>
<td align="left">24,389</td>
<td align="left">21.9%</td>
<td align="left">59,122</td>
<td align="left">18.0%</td>
</tr>
<tr>
<td align="left">50 Years and Older</td>
<td align="left">41,152</td>
<td align="left">36.9%</td>
<td align="left">55,167</td>
<td align="left">16.8%</td>
</tr>
<tr>
<td align="left"><bold>Gender</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Female</td>
<td align="left">40,284</td>
<td align="left">36.1%</td>
<td align="left">131,926</td>
<td align="left">40.2%</td>
</tr>
<tr>
<td align="left">Male</td>
<td align="left">71,150</td>
<td align="left">63.7%</td>
<td align="left">195,327</td>
<td align="left">59.5%</td>
</tr>
<tr>
<td align="left">Missing</td>
<td align="left">286</td>
<td align="left">0.3%</td>
<td align="left">959</td>
<td align="left">0.3%</td>
</tr>
<tr>
<td align="left"><bold>Race and Ethnicity</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Black or African American</td>
<td align="left">15,668</td>
<td align="left">14.0%</td>
<td align="left">50,013</td>
<td align="left">15.2%</td>
</tr>
<tr>
<td align="left">Hispanic of Any Race</td>
<td align="left">12,240</td>
<td align="left">11.00%</td>
<td align="left">39,641</td>
<td align="left">12.10%</td>
</tr>
<tr>
<td align="left">White</td>
<td align="left">62,247</td>
<td align="left">55.70%</td>
<td align="left">178,598</td>
<td align="left">54.40%</td>
</tr>
<tr>
<td align="left">Another Race</td>
<td align="left">6,474</td>
<td align="left">5.80%</td>
<td align="left">18,324</td>
<td align="left">5.60%</td>
</tr>
<tr>
<td align="left">Missing</td>
<td align="left">15,091</td>
<td align="left">13.50%</td>
<td align="left">41,636</td>
<td align="left">12.70%</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot>
<fn id="t001fn001"><p>Percentages are column percentages.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Annual count data among all cases with alcohol or substance-induced disorders may be found in <xref ref-type="fig" rid="pmen.0000706.g002">Fig 2</xref>. Examining <xref ref-type="fig" rid="pmen.0000706.g002">Fig 2</xref> shows that the total number of annual alcohol or substance-induced disorder diagnoses was higher in addiction treatment cases when observing the counts of mental health treatment cases, apart from the years 2014, 2019, 2020, and 2022. Also seen in <xref ref-type="fig" rid="pmen.0000706.g002">Fig 2</xref> is that cases with an alcohol-induced disorder had a lower count annually when observing the counts of substance-induced disorder.</p>
<fig id="pmen.0000706.g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pmen.0000706.g002</object-id><label>Fig 2</label><caption><title>Alcohol/Substance-Induced Disorder Treatment Counts in Addiction and Mental Health Treatment 2013 to 2022.</title></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.g002" xlink:type="simple"/></fig>
</sec>
<sec id="sec009">
<title>Substance use disorder treatment cases: Substances used</title>
<p>The percentage of primary substances among cases with both alcohol and substance-induced disorders receiving treatment in the substance use disorder setting may be found in <xref ref-type="fig" rid="pmen.0000706.g003">Fig 3</xref>. Alcohol was identified as the primary substance in 68.0% (68,186 / 100,331) of cases with an alcohol-induced disorder in substance use disorder treatment. Among cases with a substance-induced disorder in substance use disorder treatment, 19.0% (68,465 / 359,486) had methamphetamine as a primary substance, and 17.3% (62,117 / 359,486) had heroin as a primary substance. However, when heroin and other opiates and synthetics were combined, they accounted for the primary substance among 28.8% of cases with a substance-induced disorder.</p>
<fig id="pmen.0000706.g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pmen.0000706.g003</object-id><label>Fig 3</label><caption><title>Percentage of Primary Substances Among Addiction Treatment Episodes with Alcohol/Substance-Induced Disorders.</title><p>Combined Annual Admission Data from 2013 to 2022”.</p></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.g003" xlink:type="simple"/></fig>
<p>As some cases also had a secondary and/or tertiary substance listed, not just a primary substance, <xref ref-type="fig" rid="pmen.0000706.g004">Fig 4</xref> shows cases with any substance reported in the substance use disorder treatment setting. Alcohol was identified as being used in 79.0% (79,290 / 100,331) of cases with an alcohol-induced disorder in substance use disorder treatment. Among cases with a substance-induced disorder in substance use disorder treatment, methamphetamine use was reported among 26.4% (95,055 / 359,486) of cases, and cannabis use was reported among 23.6% (84,743 / 359,486) of cases.</p>
<fig id="pmen.0000706.g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pmen.0000706.g004</object-id><label>Fig 4</label><caption><title>Percentage of All Substances Among Addiction Treatment Episodes with Alcohol/Substance-Induced Disorders.</title><p>Combined Annual Admission Data from 2013 to 2022”.</p></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.g004" xlink:type="simple"/></fig>
</sec>
<sec id="sec010">
<title>Mental health disorder treatment cases: Mental health disorders</title>
<p>The percentage of primary mental health disorders among cases with both alcohol and substance-induced disorders receiving treatment in the mental health disorder treatment setting may be found in <xref ref-type="fig" rid="pmen.0000706.g005">Fig 5</xref>. Depressive disorders were identified as the primary mental health disorder diagnosis among 23.6% (26,417 / 111,720) of cases with an alcohol-induced disorder in mental health disorder treatment, followed by substance use disorders at 21.0% (23,433 / 111,720), and bipolar disorders at 11.7% (13,098 / 111,720). Among cases with a substance-induced disorder in mental health treatment, 30.6% (100,412 / 328,212) had a substance use disorder, followed by 15.9% (52,155 / 328,212) with a depressive disorder, and 13.3% (43,769 / 328,212) with schizophrenia or other psychotic disorders.</p>
<fig id="pmen.0000706.g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pmen.0000706.g005</object-id><label>Fig 5</label><caption><title>Percentage of Primary Mental Health Diagnoses Among Mental Health Treatment Episodes with Alcohol/Substance-Induced Disorders.</title><p>Combined Annual Data from 2013 to 2022”.</p></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.g005" xlink:type="simple"/></fig>
<p>As some cases also had a secondary and/or tertiary mental health disorder listed, not just a primary mental health disorder, <xref ref-type="fig" rid="pmen.0000706.g006">Fig 6</xref> shows cases with any mental health disorder reported in the mental health disorder treatment setting. Depressive disorders were identified among 33.6% (37,486 / 111,720) of cases with an alcohol-induced disorder in mental health disorder treatment, followed by substance use disorders at 27.8% (31,015 / 111,720) and anxiety disorders at 19.6% (21,870 / 111,720). Among cases with a substance-induced disorder in mental health disorder treatment, 36.6% (120, 288 / 328,212) had a substance use disorder, followed by 24.1% (79,106 / 328,212) with a depressive disorder, and 18.0% (59,228 / 328,212) with schizophrenia or other psychotic disorders.</p>
<fig id="pmen.0000706.g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pmen.0000706.g006</object-id><label>Fig 6</label><caption><title>Percentage of All Mental Health Diagnoses Among Mental Health Treatment Episodes with Alcohol/Substance-Induced Disorders.</title><p>Combined Annual Data from 2013 to 2022”.</p></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.g006" xlink:type="simple"/></fig>
</sec>
</sec>
<sec id="sec011" sec-type="conclusions">
<title>Discussion</title>
<p>From 2013 to 2022, among all mental health disorder treatment cases, those with an alcohol or substance-induced disorder made up 0.7% of cases. During the same period, alcohol or substance-induced disorders accounted for approximately 2.7% of all substance use disorder treatment cases. Additionally, the total cases involving either an alcohol or substance-induced disorder in mental health treatment or substance use disorder treatment numbered 439,932 and 459,817, respectively. Although cases with an alcohol or substance-induced disorder diagnosis represent a minority in either treatment setting, the roughly 900,000 cases meeting these criteria over the analytic period emphasize these conditions as being a public health concern [<xref ref-type="bibr" rid="pmen.0000706.ref016">16</xref>].</p>
<p>Considering alcohol or substance-induced disorders include different conditions such as intoxication, withdrawal, and mental conditions resulting in anxiety, depressive, psychotic, or manic symptoms [<xref ref-type="bibr" rid="pmen.0000706.ref004">4</xref>], there is variability in treatment needs and how these needs present in treatment. For example, people with intoxication or withdrawal symptoms are likely to require specialized substance use disorder treatment services. However, mental health symptoms can also emerge due to the experience of withdrawal, which is captured in many standardized withdrawal assessments. For example, the Clinical Institute Withdrawal Assessment for Alcohol-Revised [<xref ref-type="bibr" rid="pmen.0000706.ref021">21</xref>], Clinical Institute Withdrawal Assessment-Benzodiazepines [<xref ref-type="bibr" rid="pmen.0000706.ref022">22</xref>], and Subjective Opiate Withdrawal Scale [<xref ref-type="bibr" rid="pmen.0000706.ref023">23</xref>], all include anxiety/anxious as a potential symptom. Therefore, managing both the impact of the substance and subsequent mental health symptoms can enhance the care that individuals receive [<xref ref-type="bibr" rid="pmen.0000706.ref005">5</xref>–<xref ref-type="bibr" rid="pmen.0000706.ref012">12</xref>]. Variability in the conditions that are induced and the severity of these substance-induced disorders are impacted by the specific substance or substances that the person uses [<xref ref-type="bibr" rid="pmen.0000706.ref001">1</xref>].</p>
<p>This study examined all listed and primary substances reported among cases that received substance use disorder treatment. As might be expected, the majority (79%) of cases with an alcohol-induced disorder in substance use disorder treatment were identified as reporting alcohol use, with 68% having alcohol listed as their primary substance. Heroin and other opiates and synthetics accounted for the primary substance among 28.8% of cases with a substance-induced disorder in the substance use disorder treatment data. One study found that among 31,134 treatment episodes initiating medication for opioid use disorder, such as buprenorphine, approximately 3.5% had a substance-induced mental health disorder [<xref ref-type="bibr" rid="pmen.0000706.ref024">24</xref>]. Further, that study found that among persons with an opioid use disorder, developing a subsequent substance-induced mental health disorder was associated with leaving treatment prematurely [<xref ref-type="bibr" rid="pmen.0000706.ref024">24</xref>]. This highlights the importance of addressing mental health symptoms and conditions that may emerge due to substance use. Approximately 1 in 5 cases with a substance-induced disorder had methamphetamine listed as the primary substance. Methamphetamine-induced psychosis is a known mental health consequence of methamphetamine use and should be addressed in treatment to avoid persons returning to previous patterns of use [<xref ref-type="bibr" rid="pmen.0000706.ref025">25</xref>,<xref ref-type="bibr" rid="pmen.0000706.ref026">26</xref>]. Unlike other drug classes commonly identified in substance use treatment, such as alcohol, nicotine, opioids, and tobacco, there are no approved pharmacotherapies for methamphetamine. However, behavioral therapies such as contingency management may assist in treating a substance use disorder due to methamphetamine.[<xref ref-type="bibr" rid="pmen.0000706.ref027">27</xref>]</p>
<p>This study also examined all listed and primary mental health diagnoses reported among cases that received mental health treatment. Approximately 1 in 3 cases with an alcohol-induced disorder and 1 in 4 cases with a substance-induced disorder had a depressive disorder diagnosis. When considering the primary diagnosis, approximately 1 in 4 cases with an alcohol-induced disorder and 15% of cases with a substance-induced disorder had a depressive disorder as the primary diagnosis. A review of the literature suggests that more studies are needed to distinguish substance-induced mood disorders from comorbid mood disorders in individuals with substance use disorders, as the review found inconsistent results regarding risk factors and symptoms [<xref ref-type="bibr" rid="pmen.0000706.ref002">2</xref>]. This is an important clinical consideration since mental health disorders often co-occur with substance use disorders. However, for a mood disorder to be classified as substance-induced, substance use must be the causal factor for the condition. A study from 2012 examining 58 persons who use substances and have a mood disorder in a psychiatric unit identified that major depressive episodes were substance-induced in 72% of individuals, and more specifically, regarding the substance, 57% were alcohol-induced major depressive episodes [<xref ref-type="bibr" rid="pmen.0000706.ref028">28</xref>].</p>
<p>As seen in <xref ref-type="fig" rid="pmen.0000706.g005">Fig 5</xref> and <xref ref-type="fig" rid="pmen.0000706.g006">6</xref>, bipolar disorders and schizophrenia or other psychotic disorders were in the top five of all reported mental health diagnoses and primary diagnoses. Subsequent transition from substance-induced psychosis to bipolar or schizophrenia/other psychotic disorders has been documented in the literature. The risk of transition to schizophrenia spectrum disorder is higher than the risk of transition to bipolar disorder [<xref ref-type="bibr" rid="pmen.0000706.ref029">29</xref>]. Overall, findings from this study revealed a high level of clinical co-morbidity, with several mental health disorders showing a high prevalence among cases in the mental health treatment data.</p>
<p>Findings from this study suggest potential avenues for future research. First, given the often-separate expertise of mental health disorder treatment facilities and substance use disorder treatment facilities [<xref ref-type="bibr" rid="pmen.0000706.ref030">30</xref>], studies of clinical outcomes should be conducted in both settings. Further, clinical outcomes in this sample should be examined in settings that provide only mental health or substance use disorder treatment, compared with facilities that provide integrated treatment for co-occurring mental health/substance use disorders. Future studies that can discern whether outcomes differ by the treatment facility’s specialty can provide insights into effective interventions for this clinical population. Another avenue for future research is examining the combined clinical course of the sample based on co-occurring diagnoses, such as alcohol use disorder and depressive disorder, potentially co-occurring with the induced disorder. Identifying whether the clinical course differs between those with and without a co-occurring mental health disorder when an alcohol or substance-induced disorder emerges would be a useful contribution to the literature to inform clinical care.</p>
<sec id="sec012">
<title>Limitation</title>
<p>Despite employing robust statistical tools in exploring alcohol and substance-induced disorders in both mental health and substance use disorder treatments, limitations must be acknowledged. The Mental Health Client-Level Data [<xref ref-type="bibr" rid="pmen.0000706.ref017">17</xref>] and the Treatment Episode Data Set Admissions [<xref ref-type="bibr" rid="pmen.0000706.ref015">15</xref>] differ in units of analysis, with individuals and treatment episodes serving as the respective units. Another limitation is that the mental health treatment data includes diagnoses of mental health disorders, while the substance use disorder treatment data considers substance use as a primary, secondary, or tertiary clinical factor. This makes it difficult to consistently analyze variables across both datasets. Additionally, while alcohol-induced disorder is listed as a separate category from substance-induced disorder in these datasets, substance-induced disorder is broadly defined as conditions caused by substance use, including alcohol, based on diagnostic criteria [<xref ref-type="bibr" rid="pmen.0000706.ref001">1</xref>]. Consequently, since this is real-world treatment data, some cases categorized as substance-induced disorders may involve alcohol as the substance. While this study provides an overall description of these cases falling under the umbrella of mental health or substance use disorder treatment, future studies are needed to examine specific levels of care such as residential treatment or outpatient treatment. Future studies examining different levels of care are needed, as outpatient treatment is typically provided to persons with less severe conditions or more stable environmental support than those in inpatient or residential treatment. Another limitation is that intoxication, withdrawal, and mental health issues are grouped under the broad diagnostic category of substance-induced disorder [<xref ref-type="bibr" rid="pmen.0000706.ref001">1</xref>], but the datasets lack specific variables to determine which particular type of substance-induced disorder applies in each case. While this study identifies cases that have a reported alcohol- or substance-induced disorder, the true prevalence of these conditions cannot be determined in either dataset as not all people entering treatment may have been screened for these conditions. Further, the “DSMCRIT” and “SUB” variables allow only one category per case, and other categories, such as cocaine abuse, are permitted in these variables.</p>
</sec>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Conclusion</title>
<p>This descriptive epidemiological study found that alcohol-induced disorder cases made up 0.2%, while substance-induced disorder cases accounted for 0.5% of the total national mental health treatment data. Substance-induced disorders are a significant public health concern, and more research is needed to better understand the clinical needs of this population [<xref ref-type="bibr" rid="pmen.0000706.ref016">16</xref>]. Future research should focus on analyzing demographic trends of individuals with these conditions, assessing the effectiveness of treatments, identifying the most commonly used substances each year within this sample, and determining the most prevalent co-occurring mental health disorders annually among this sample.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pmen.0000706.ref001"><label>1</label><mixed-citation publication-type="book" xlink:type="simple"><collab>American Psychiatric Association</collab>. <source>Diagnostic and statistical manual of mental disorders</source>. <edition designator="5">5th ed., text rev. ed</edition>. <publisher-name>American Psychiatric Association</publisher-name>. <year>2022</year>.</mixed-citation></ref>
<ref id="pmen.0000706.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kivlichan</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Praecht</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>George</surname> <given-names>TP</given-names></name>. <article-title>Substance-Induced Mood Disorders: A Scoping Review</article-title>. <source>Curr Addict Rep</source>. <year>2024</year>;<volume>11</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>18</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40429-023-00533-z" xlink:type="simple">10.1007/s40429-023-00533-z</ext-link></comment></mixed-citation></ref>
<ref id="pmen.0000706.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Langås</surname> <given-names>A-M</given-names></name>, <name name-style="western"><surname>Malt</surname> <given-names>UF</given-names></name>, <name name-style="western"><surname>Opjordsmoen</surname> <given-names>S</given-names></name>. <article-title>Independent versus substance-induced major depressive disorders in first-admission patients with substance use disorders: an exploratory study</article-title>. <source>J Affect Disord</source>. <year>2013</year>;<volume>144</volume>(<issue>3</issue>):<fpage>279</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jad.2012.10.008" xlink:type="simple">10.1016/j.jad.2012.10.008</ext-link></comment> <object-id pub-id-type="pmid">23158758</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref004"><label>4</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Revadigar</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Gupta</surname> <given-names>V</given-names></name>. <source>Substance-induced mood disorders</source>. <publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls</publisher-name>. <year>2025</year>.</mixed-citation></ref>
<ref id="pmen.0000706.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aggarwal</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Banerjee</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Singh</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Mattoo</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Basu</surname> <given-names>D</given-names></name>. <article-title>Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications</article-title>. <source>Asian J Psychiatr</source>. <year>2012</year>;<volume>5</volume>(<issue>3</issue>):<fpage>220</fpage>–<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajp.2011.11.008" xlink:type="simple">10.1016/j.ajp.2011.11.008</ext-link></comment> <object-id pub-id-type="pmid">22981049</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bramness</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Hjorthøj</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Niemelä</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Taipale</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rognli</surname> <given-names>EB</given-names></name>. <article-title>Discussing the concept of substance-induced psychosis (SIP)</article-title>. <source>Psychol Med</source>. <year>2024</year>;<volume>54</volume>(<issue>11</issue>):<fpage>2852</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S0033291724001442" xlink:type="simple">10.1017/S0033291724001442</ext-link></comment> <object-id pub-id-type="pmid">39252388</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fiorentini</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cantu</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Crisanti</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Cereda</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Oldani</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Brambilla</surname> <given-names>P</given-names></name>. <article-title>Substance-Induced Psychoses: An Updated Literature Review</article-title>. <source>Front Psychiatry</source>. <year>2021</year>;<volume>12</volume>:<fpage>694863</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2021.694863" xlink:type="simple">10.3389/fpsyt.2021.694863</ext-link></comment> <object-id pub-id-type="pmid">35002789</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garson</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Castle</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>George</surname> <given-names>TP</given-names></name>. <article-title>Substance-Induced Psychosis: a Narrative Review</article-title>. <source>Curr Addict Rep</source>. <year>2023</year>;<volume>10</volume>(<issue>2</issue>):<fpage>335</fpage>–<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40429-023-00475-6" xlink:type="simple">10.1007/s40429-023-00475-6</ext-link></comment></mixed-citation></ref>
<ref id="pmen.0000706.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gicas</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Parmar</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Fabiano</surname> <given-names>GF</given-names></name>, <name name-style="western"><surname>Mashhadi</surname> <given-names>F</given-names></name>. <article-title>Substance-induced psychosis and cognitive functioning: A systematic review</article-title>. <source>Psychiatry Res</source>. <year>2022</year>;<volume>308</volume>:<fpage>114361</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.psychres.2021.114361" xlink:type="simple">10.1016/j.psychres.2021.114361</ext-link></comment> <object-id pub-id-type="pmid">34979380</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karimi</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Pooyanmehr</surname> <given-names>N</given-names></name>. <article-title>Substances led to Psychosis: A Systematic Review</article-title>. <source>TOPSYJ</source>. <year>2024</year>;<volume>17</volume>(<issue>1</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/0118743501297735240510161825" xlink:type="simple">10.2174/0118743501297735240510161825</ext-link></comment></mixed-citation></ref>
<ref id="pmen.0000706.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mathias</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lubman</surname> <given-names>DI</given-names></name>, <name name-style="western"><surname>Hides</surname> <given-names>L</given-names></name>. <article-title>Substance-induced psychosis: a diagnostic conundrum</article-title>. <source>J Clin Psychiatry</source>. <year>2008</year>;<volume>69</volume>(<issue>3</issue>):<fpage>358</fpage>–<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4088/jcp.v69n0304" xlink:type="simple">10.4088/jcp.v69n0304</ext-link></comment> <object-id pub-id-type="pmid">18278990</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wilson</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Szigeti</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kearney</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Clarke</surname> <given-names>M</given-names></name>. <article-title>Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: A systematic review</article-title>. <source>Schizophr Res</source>. <year>2018</year>;<volume>197</volume>:<fpage>78</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.schres.2017.11.001" xlink:type="simple">10.1016/j.schres.2017.11.001</ext-link></comment> <object-id pub-id-type="pmid">29117908</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lesko</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Fox</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Edwards</surname> <given-names>JK</given-names></name>. <article-title>A Framework for Descriptive Epidemiology</article-title>. <source>Am J Epidemiol</source>. <year>2022</year>;<volume>191</volume>(<issue>12</issue>):<fpage>2063</fpage>–<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/aje/kwac115" xlink:type="simple">10.1093/aje/kwac115</ext-link></comment> <object-id pub-id-type="pmid">35774001</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref014"><label>14</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>L</given-names></name>. <article-title>Chapter 1 - Introduction</article-title>. <source>Heart Failure: Epidemiology and Research Methods</source>. <publisher-name>Elsevier</publisher-name>. <year>2018</year>. p. <fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation></ref>
<ref id="pmen.0000706.ref015"><label>15</label><mixed-citation publication-type="other" xlink:type="simple"><collab>Substance Abuse and Mental Health Services Administration</collab>. Treatment Episode Data Set. <year>2025</year>. <ext-link ext-link-type="uri" xlink:href="https://www.samhsa.gov/data/data-we-collect/teds-treatment-episode-data-set" xlink:type="simple">https://www.samhsa.gov/data/data-we-collect/teds-treatment-episode-data-set</ext-link></mixed-citation></ref>
<ref id="pmen.0000706.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fedotov</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Shustov</surname> <given-names>D</given-names></name>. <article-title>Three Waves of Substance-Induced Mental Disorders over the Past 30 Years: Results from a Retrospective Observational Cohort Analysis</article-title>. <source>TOBIOIJ</source>. <year>2025</year>;<volume>18</volume>(<issue>1</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/0118750362402771250908034339" xlink:type="simple">10.2174/0118750362402771250908034339</ext-link></comment></mixed-citation></ref>
<ref id="pmen.0000706.ref017"><label>17</label><mixed-citation publication-type="book" xlink:type="simple"><collab>Substance Abuse and Mental Health Services Administration</collab>. <source>Mental Health Client-Level Data (MH-CLD)</source>. <publisher-name>Substance Abuse and Mental Health Services Administration</publisher-name>. <year>2025</year>. <ext-link ext-link-type="uri" xlink:href="https://www.samhsa.gov/data/data-we-collect/mh-cld-mental-health-client-level-data/datafiles" xlink:type="simple">https://www.samhsa.gov/data/data-we-collect/mh-cld-mental-health-client-level-data/datafiles</ext-link></mixed-citation></ref>
<ref id="pmen.0000706.ref018"><label>18</label><mixed-citation publication-type="other" xlink:type="simple"><collab>IBM Corp</collab>. IBM SPSS Statistics: Version 31.0. <year>2025</year>.</mixed-citation></ref>
<ref id="pmen.0000706.ref019"><label>19</label><mixed-citation publication-type="book" xlink:type="simple"><collab>R Core Team</collab>. <source>R: A language and environment for statistical computing</source>. <publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>. <year>2025</year>.</mixed-citation></ref>
<ref id="pmen.0000706.ref020"><label>20</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Wickham</surname> <given-names>H</given-names></name>. <source>ggplot2: Elegant graphics for data analysis</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer-Verilog</publisher-name>; <year>2016</year>.</mixed-citation></ref>
<ref id="pmen.0000706.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sullivan</surname> <given-names>JT</given-names></name>, <name name-style="western"><surname>Sykora</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Schneiderman</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Naranjo</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Sellers</surname> <given-names>EM</given-names></name>. <article-title>Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)</article-title>. <source>Br J Addict</source>. <year>1989</year>;<volume>84</volume>(<issue>11</issue>):<fpage>1353</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1360-0443.1989.tb00737.x" xlink:type="simple">10.1111/j.1360-0443.1989.tb00737.x</ext-link></comment> <object-id pub-id-type="pmid">2597811</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Busto</surname> <given-names>UE</given-names></name>, <name name-style="western"><surname>Sykora</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sellers</surname> <given-names>EM</given-names></name>. <article-title>A clinical scale to assess benzodiazepine withdrawal</article-title>. <source>J Clin Psychopharmacol</source>. <year>1989</year>;<volume>9</volume>(<issue>6</issue>):<fpage>412</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/00004714-198912000-00005" xlink:type="simple">10.1097/00004714-198912000-00005</ext-link></comment> <object-id pub-id-type="pmid">2574193</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Handelsman</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Cochrane</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Aronson</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Ness</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rubinstein</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Kanof</surname> <given-names>PD</given-names></name>. <article-title>Two new rating scales for opiate withdrawal</article-title>. <source>Am J Drug Alcohol Abuse</source>. <year>1987</year>;<volume>13</volume>(<issue>3</issue>):<fpage>293</fpage>–<lpage>308</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3109/00952998709001515" xlink:type="simple">10.3109/00952998709001515</ext-link></comment> <object-id pub-id-type="pmid">3687892</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tilhou</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Grucza</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>KY</given-names></name>. <article-title>Substance-induced mental disorders and discontinuation of medication for opioid use disorder</article-title>. <source>Drug Alcohol Depend</source>. <year>2025</year>;<volume>272</volume>:<fpage>112685</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.drugalcdep.2025.112685" xlink:type="simple">10.1016/j.drugalcdep.2025.112685</ext-link></comment> <object-id pub-id-type="pmid">40319789</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Glasner-Edwards</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mooney</surname> <given-names>LJ</given-names></name>. <article-title>Methamphetamine psychosis: epidemiology and management</article-title>. <source>CNS Drugs</source>. <year>2014</year>;<volume>28</volume>(<issue>12</issue>):<fpage>1115</fpage>–<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40263-014-0209-8" xlink:type="simple">10.1007/s40263-014-0209-8</ext-link></comment> <object-id pub-id-type="pmid">25373627</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref026"><label>26</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>McKetin</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kaye</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Clemens</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Hermens</surname> <given-names>D</given-names></name>. <article-title>Methamphetamine Addiction.</article-title> In: Miller PM, editor. <source>Principles of Addiction</source>. <publisher-loc>San Diego</publisher-loc>: <publisher-name>Academic Press</publisher-name>. <year>2013</year>. p. <fpage>689</fpage>–<lpage>98</lpage>.</mixed-citation></ref>
<ref id="pmen.0000706.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brown</surname> <given-names>HD</given-names></name>, <name name-style="western"><surname>DeFulio</surname> <given-names>A</given-names></name>. <article-title>Contingency management for the treatment of methamphetamine use disorder: A systematic review</article-title>. <source>Drug Alcohol Depend</source>. <year>2020</year>;<volume>216</volume>:<fpage>108307</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.drugalcdep.2020.108307" xlink:type="simple">10.1016/j.drugalcdep.2020.108307</ext-link></comment> <object-id pub-id-type="pmid">33007699</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Helseth</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Samet</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Johnsen</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bramness</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Waal</surname> <given-names>H</given-names></name>. <article-title>Independent or Substance-Induced Mental Disorders? An Investigation of Comorbidity in an Acute Psychiatric Unit</article-title>. <source>Journal of Dual Diagnosis</source>. <year>2013</year>;<volume>9</volume>(<issue>1</issue>):<fpage>78</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/15504263.2012.749142" xlink:type="simple">10.1080/15504263.2012.749142</ext-link></comment></mixed-citation></ref>
<ref id="pmen.0000706.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rognli</surname> <given-names>EB</given-names></name>, <name name-style="western"><surname>Heiberg</surname> <given-names>IH</given-names></name>, <name name-style="western"><surname>Jacobsen</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Høye</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bramness</surname> <given-names>JG</given-names></name>. <article-title>Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder</article-title>. <source>Am J Psychiatry</source>. <year>2023</year>;<volume>180</volume>(<issue>6</issue>):<fpage>437</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1176/appi.ajp.22010076" xlink:type="simple">10.1176/appi.ajp.22010076</ext-link></comment> <object-id pub-id-type="pmid">37132221</object-id></mixed-citation></ref>
<ref id="pmen.0000706.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spivak</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Strain</surname> <given-names>EC</given-names></name>, <name name-style="western"><surname>Spivak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cullen</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ruble</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Parekh</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Integrated dual diagnosis treatment among United States mental health treatment facilities: 2010 to 2018</article-title>. <source>Drug Alcohol Depend</source>. <year>2020</year>;<volume>213</volume>:<fpage>108074</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.drugalcdep.2020.108074" xlink:type="simple">10.1016/j.drugalcdep.2020.108074</ext-link></comment> <object-id pub-id-type="pmid">32512404</object-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pmen.0000706.r001" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r001</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>Ahmed</surname>
<given-names>Gellan Karamallah Ramadan</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Gellan Karamallah Ramadan Ahmed</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="article" id="rel-obj001" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="letter-date">10 Dec 2025</named-content></p>
<p>PMEN-D-25-00524</p>
<p>Alcohol and Substance-Induced Disorder Treatment Cases in Mental Health and Addiction Treatment Facilities from 2013 to 2022</p>
<p>PLOS Mental Health</p>
<p>Dear Dr. Ware,</p>
<p>Thank you for submitting your manuscript to PLOS Mental Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Mental Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Please submit your revised manuscript by Jan 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">mentalhealth@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pmen/" xlink:type="simple">https://www.editorialmanager.com/pmen/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<list list-type="bullet">
<list-item>
<p>A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
</list-item>
<list-item>
<p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
</list-item>
<list-item>
<p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
</list-item>
</list>
<p>Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Gellan Karamallah Ramadan Ahmed</p>
<p>Academic Editor</p>
<p>PLOS Mental Health</p>
<p>Journal Requirements:</p>
<p>If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.</p>
<p>Additional Editor Comments (if provided):</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><bold>Comments to the Author</bold></p>
<p>1. Does this manuscript meet PLOS Mental Health’s <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/criteria-for-publication" xlink:type="simple">publication criteria</ext-link>?&gt;</p>
<p>Reviewer #1: Partly</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>2. Has the statistical analysis been performed appropriately and rigorously?--&gt;?&gt;</p>
<p>Reviewer #1: N/A</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??&gt;</p>
<p>The <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/data-availability" xlink:type="simple">PLOS Data policy</ext-link></p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>4. Is the manuscript presented in an intelligible fashion and written in standard English??&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>Reviewer #1: This manuscript provides a national-level analysis of alcohol-induced and substance-induced disorder diagnoses across U.S. mental health and substance use disorder (SUD) treatment systems from 2013–2022. The manuscript is generally well written, methodologically straightforward, and supported by appropriate data sources. However, it would benefit from stronger framing, greater methodological clarity, more detailed analysis of trends, and a more nuanced discussion connecting the results to existing literature. Several limitations also need more explicit and specific treatment.</p>
<p>Overall, I recommend major revisions to strengthen interpretation, clarity, and methodological transparency.</p>
<p>The aim of the article is not clearly stated in the abstract, and emphasizing it more explicitly would help readers understand the purpose and contribution of the study. Additionally, although the paper claims to analyze trends, it does not clearly describe how the reported values change over time. The revised manuscript should be consistent—either functioning as a high-level summary or offering an account of periodical change.</p>
<p>I also noted that Table 1 does not appear to be referenced in the text. The figures are difficult to read and appear pixelated; higher-resolution images would improve readability.</p>
<p>Regarding lines 309–310, the statement about further research is broad and therefore not very informative. The authors should be more precise about what types of future research are needed. For example, it would be helpful to specify what kinds of studies could translate these descriptive findings into actionable steps to improve interventions and enhance care for this population.</p>
<p>Reviewer #2: Thank you very much for the opportunity to review this interesting article. The subject matter discussed would be, I believe, of interest to the readership of PLOS Mental Health. However, my main concern centres around the analysis of what is a very large dataset, which has the potential to provide significant insight. The study only considers univariate statistics in the analysis, while it would be useful to see, as you say, “national trends of alcohol or substance-induced disorders in the mental health treatment setting alongside substance use disorder cases”. Multivariate analysis would be welcomed here, and I would advise discussing with a statistician the best approach to take to conduct robust analysis. This should lead to a significant revision and strengthening of the discussion section, in which I would advise that you think much more carefully about what the results are and are not showing you, and the potential implications of this.</p>
<p>In summary, while the paper has the potential to offer important insights in this area, more robust analysis and discussion is first required.</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalthealth/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold>  If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p>For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link></p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pmen.0000706.r002">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r002</article-id>
<title-group>
<article-title>Author response to Decision Letter 1</article-title>
</title-group>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj002" link-type="rebutted-decision-letter" object-id="10.1371/journal.pmen.0000706.r001" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="author-response-date">2 Jan 2026</named-content></p>
<supplementary-material id="pmen.0000706.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.s002" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Reviewer Response.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pmen.0000706.r003" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r003</article-id>
<title-group>
<article-title>Decision Letter 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>Ahmed</surname>
<given-names>Gellan Karamallah Ramadan</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Gellan Karamallah Ramadan Ahmed</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="article" id="rel-obj003" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="letter-date">22 Jan 2026</named-content></p>
<p>PMEN-D-25-00524R1</p>
<p>Alcohol and Substance-Induced Disorder Treatment Cases in Mental Health and Addiction Treatment Facilities from 2013 to 2022: A Descriptive Study</p>
<p>PLOS Mental Health</p>
<p>Dear Dr. Ware,</p>
<p>Thank you for submitting your manuscript to PLOS Mental Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Mental Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Please submit your revised manuscript by Feb 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">mentalhealth@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pmen/" xlink:type="simple">https://www.editorialmanager.com/pmen/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<list list-type="bullet">
<list-item>
<p>A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
</list-item>
<list-item>
<p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
</list-item>
<list-item>
<p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
</list-item>
</list>
<p>Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Gellan Karamallah Ramadan Ahmed</p>
<p>Academic Editor</p>
<p>PLOS Mental Health</p>
<p>Journal Requirements:</p>
<p>If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.</p>
<p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
<p>Additional Editor Comments (if provided):</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><bold>Comments to the Author</bold></p>
<p>Reviewer #1: All comments have been addressed</p>
<p>Reviewer #2: (No Response)</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/criteria-for-publication" xlink:type="simple">publication criteria</ext-link>?&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Partly</p>
<p>**********</p>
<p>3. Has the statistical analysis been performed appropriately and rigorously?--&gt;?&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??&gt;</p>
<p>The <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/data-availability" xlink:type="simple">PLOS Data policy</ext-link></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>5. Is the manuscript presented in an intelligible fashion and written in standard English??&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>Reviewer #1: My concerns have been adressed.</p>
<p>Reviewer #2: Thank you for the submission of your revised article. You have clarified that as this is a descriptive study, no further analysis will be done. As per Lesko et al. (2022) <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/aje/kwac115" xlink:type="simple">https://doi.org/10.1093/aje/kwac115</ext-link> which has guided your study, further detail is still required as to the action(s) that might be informed by the results that you have found.</p>
<p>Your interpretation also requires greater depth, specifically regarding how the aforementioned results could inform or improve future practice and outcomes and the future research that is required for this to be feasible. For example, why would it be important for future research to examine inpatient compared to outpatient data? What would the clinical significance be to this?</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold>  If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p>For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link></p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pmen.0000706.r004">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r004</article-id>
<title-group>
<article-title>Author response to Decision Letter 2</article-title>
</title-group>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj004" link-type="rebutted-decision-letter" object-id="10.1371/journal.pmen.0000706.r003" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>2</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="author-response-date">5 Feb 2026</named-content></p>
<supplementary-material id="pmen.0000706.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.s003" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pmen.0000706.r005" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r005</article-id>
<title-group>
<article-title>Decision Letter 2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>Ahmed</surname>
<given-names>Gellan Karamallah Ramadan</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Gellan Karamallah Ramadan Ahmed</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="article" id="rel-obj005" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>2</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="letter-date">22 Apr 2026</named-content></p>
<p>PMEN-D-25-00524R2</p>
<p>Alcohol and Substance-Induced Disorder Treatment Cases in Mental Health and Addiction Treatment Facilities from 2013 to 2022: A Descriptive Study</p>
<p>PLOS Mental Health</p>
<p>Dear Dr. Ware,</p>
<p>Thank you for submitting your manuscript to PLOS Mental Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Mental Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Please submit your revised manuscript by May 22 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">mentalhealth@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pmen/" xlink:type="simple">https://www.editorialmanager.com/pmen/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<list list-type="bullet">
<list-item>
<p>A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
</list-item>
<list-item>
<p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
</list-item>
<list-item>
<p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
</list-item>
</list>
<p>Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. <italic>Only</italic>  the individual author can complete the verification step; PLOS staff <italic>cannot</italic>  verify ORCID iDs on behalf of authors.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Gellan Karamallah Ramadan Ahmed</p>
<p>Academic Editor</p>
<p>PLOS Mental Health</p>
<p><bold>Journal Requirements:</bold></p>
<p>If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.</p>
<p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
<p><bold>Additional Editor Comments (if provided):</bold></p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><bold>Comments to the Author</bold></p>
<p>Reviewer #3: (No Response)</p>
<p>Reviewer #4: (No Response)</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/criteria-for-publication" xlink:type="simple">publication criteria</ext-link>?&gt;</p>
<p>Reviewer #3: Yes</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>3. Has the statistical analysis been performed appropriately and rigorously?--&gt;?&gt;</p>
<p>Reviewer #3: Yes</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??&gt;</p>
<p>The <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/data-availability" xlink:type="simple">PLOS Data policy</ext-link></p>
<p>Reviewer #3: Yes</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>5. Is the manuscript presented in an intelligible fashion and written in standard English??&gt;</p>
<p>Reviewer #3: Yes</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p><bold>Reviewer #3:</bold>  Lines 89 to 93: ‘Due to this gap, one study analyzed the Substance 90 Abuse and Mental Health Services Administration’s Treatment Episode Data Set 91 Admissions [15], reviewing all cases identified as having a “substance-induced disorder” 92 from 1992 to 2022, excluding cases with an “alcohol-induced disorder" unless 93 examining trends of these diagnoses [16]’. The beginning of this argument ‘Due to this gap’ is weak. Kindly rephrase.</p>
<p>Lines 104- 111: ‘[a] Identify the percentage of cases flagged as having 105 alcohol-induced disorders or substance-induced disorders in mental health and 106 substance use disorder treatment settings, [b.] Examine the prevalence of other mental 107 health diagnoses, such as anxiety and depressive disorders, among cases with alcohol108 induced disorders or substance-induced disorders in mental health treatment, and [c.] 109 Examine the prevalence of substances used, such as alcohol and cannabis, among 110 cases with alcohol-induced disorders or substance-induced disorders in mental health 111 treatment’. You do not need to enumerate your objectives. I will advise that you report the main study objective and other specific study objectives can be discussed in the ‘Discussion section’.</p>
<p>Lines 225-228: ‘Building upon the research by Fedotov and Shustov [16], which examined substance226 induced disorder treatment in the addiction setting, this is the first study to analyze 227 alcohol-induced and substance-induced disorders in national treatment records for 228 mental health and substance use issues in the United States’. This is not necessary here. The statement was mentioned earlier in the Introduction section (lines 95- 100). The first paragraph of your discussion section should report the main findings of your study.</p>
<p>Lines 343- 359: ‘Conclusion’. Your conclusion is weak. You do not have to repeat your results in the conclusion. You are only to provide your readers with a summary of the interesting findings or novel findings of your research, not necessarily repeating figures from the results. Recommend in one or two succinct paragraphs and maybe make a key recommendation for future research.</p>
<p><bold>Reviewer #4:</bold>  Address</p>
<p>Thank you for submitting a revised manuscript.</p>
<p>Summary</p>
<p>This is a descriptive study that assesses alcohol and substance-induced disorder treatment cases in mental health and addiction treatment facilities in the USA from 2013 to 2022. Secondary data was obtained from the Mental Health Client-Level Data and the Treatment Episode Data Set Admissions. Overall, the study is academically and clinically relevant. However, there are a few concerns.</p>
<p>General comments</p>
<p>The term “flagged”, though correct, should be reconsidered. Terms such as “identified”, implicated, etc., are more suitable for a study of this nature.</p>
<p>Also, there are a few grammatical errors that require the author’s attention. Example:</p>
<p>“For example, persons presenting to treatment…” Page 7; line 242</p>
<p>The author should kindly go through the entire manuscript and make the necessary corrections.</p>
<p>Furthermore, some of the sentences are quite long and difficult to read. Example:</p>
<p>“To further explore clinical diagnostic considerations, this study also examines mental health diagnoses reported in those receiving mental health treatment and substances used among individuals with an alcohol or substance-induced disorder who received treatment in either setting between 2013 and 2022.” Page 3; lines 100-103</p>
<p>The long sentences should be made shorter, if possible.</p>
<p>Finally, it will be insightful to know the following trends:</p>
<p>a. Mental disorder with the highest prevalence for each year (between 2013 and 2022).</p>
<p>b. The age group with the highest prevalence of “substance-induced mental disorder” and “alcohol-induced mental disorder” for each year (between 2013 and 2022).</p>
<p>c. Most reported substances for each year (between 2013 and 2022).</p>
<p>d. Sex and race distribution for a, b, and c for each year (between 2013 and 2022).</p>
<p>This will inform policy-makers whether the implicated age group, mental disorders, and substances with the highest prevalence are changing over the years, and advise the design of further studies and interventions.</p>
<p>The author can ignore the final point if it is out of the study’s scope.</p>
<p>Abstract</p>
<p>The abstract provides a sufficient summary of the background, methods, results, and conclusion of the study.</p>
<p>Introduction</p>
<p>“The mental health symptoms resulting from substance-induced disorders are particularly unique, as clinicians must address both the emerging psychological issues and the underlying substance use. In fact, individuals with substance-induced mental health symptoms, such as substance-induced psychosis [5-12], require treatment that considers both mental health and substance use concerns.” Page 3; lines 78-83</p>
<p>The highlighted statement appears to give clarity to the preceding statement. However, the terms and construct make it look similar to the preceding statement. The author can cite specific disorders to better clarify the preceding statement. See below:</p>
<p>“The mental health symptoms resulting from substance-induced disorders are particularly unique, as clinicians are required to address both the emerging psychological issues and the underlying substance use. For example, in the management of alcohol-induced psychotic disorder, it is recommended that the treatment address the psychotic disorder and alcohol use concern.”</p>
<p>Or</p>
<p>“The mental health symptoms resulting from substance-induced disorders are particularly unique, as clinicians are required to address both the emerging psychological issues and the underlying substance use. For example, in the management of cannabis-induced psychotic disorder, it is recommended that the treatment address the psychotic disorder and the concern of cannabis use.”</p>
<p>“Given the unique nature of substance-induced disorders, it is reasonable that facilities specializing in treating mental health disorders, substance use disorders, or both may encounter individuals with these conditions. However, the literature lacks descriptive studies [13, 14] on substance-induced disorder cases within both mental health and substance use treatment settings, alongside clinical characteristics such as substances used and mental health diagnoses.” Page 3; lines 84-89</p>
<p>I humbly submit that the statement above can be improved. I appreciate the intent of the author in trying to link the substance-induced mental disorders with the settings in which they are managed. However, the construction makes it difficult to get the correlation. Also, the succeeding sentence on descriptive studies can be re-examined. The author should kindly consider the construction of the statement above to improve the flow between the sentences and to clearly indicate the import of the statement. Finally, references 13 and 14 talk about the framework for descriptive epidemiology and heart failure epidemiology, respectively. The context of the limited descriptive studies mentioned in those papers, in my humble opinion, is related to their subject of study. While I acknowledge that references 13 and 14 support the author’s argument that there is a (general) lack of descriptive studies, it will be more appropriate to demonstrate, specifically, that there is a lack of descriptive studies on alcohol and substance-induced disorder treatment cases in mental health and addiction treatment facilities. This will further justify the current study.</p>
<p>Materials and Methods</p>
<p>Efforts to access data were unsuccessful. The final decision concerning the validity of the findings, based on the data, rests with the editor.</p>
<p>Results</p>
<p>• Figures</p>
<p>Some of the figures, as acknowledged by the author, are blurry and difficult to read. The author may consider alternative ways to improve the visuals, if possible.</p>
<p>Discussion</p>
<p>The author reports on the prevalence of Mental Health and Substance Use Disorder Treatment Cases, Substances Used, and Mental Health Disorders under “Results”. However, it is difficult to link the author’s interpretation and reasons for the observed findings to the reported results. The author should please dwell on available studies to overtly explain why the observed “prevalences” of the alcohol-induced disorder, substance-induced disorder, implicated mental disorders, and specific substances were noticed in this current study. This can be done in the light of other national, regional, continental, or global studies.</p>
<p>Limitation</p>
<p>“Future studies examining different levels of care are needed, as outpatient treatment is typically provided to persons with less severe conditions or more stable environmental support than those in inpatient or residential treatment. Therefore, these different levels of care may often represent different client populations receiving services.” Page 9; lines 330-334</p>
<p>In my humble opinion, the highlighted statement appears redundant.</p>
<p>“While this study identifies cases flagged as having an alcohol- or substance-induced disorder, the true prevalence of these conditions cannot be determined in either dataset.” Page 9; lines 338-340.</p>
<p>While the sincerity of the author, with respect to the limitations of the study, is acknowledged, the inability to identify the true prevalence of the parameters being assessed raises some concern. This is because the unanswered gap (prevalence) is part of the aims of the study.</p>
<p>Conclusion</p>
<p>It will be helpful to include the findings of the common mental health disorders and implicated substances identified in the study as part of the conclusion. This is because these parameters are part of the aim.</p>
<p>References</p>
<p>“Substance-induced disorders are a category of conditions caused by substance use” (ref). Page 3; line 75</p>
<p>“In fact, individuals with substance-induced mental health symptoms, such as substance-induced psychosis [5-12], require treatment that considers both mental health and substance use concerns” (ref). Page 3; lines 81-83</p>
<p>“Therefore, managing both the impact of the substance and subsequent mental health symptoms can enhance the care that individuals receive (ref). Variability in the conditions that are induced and the severity of these substance-induced disorders are impacted by the specific substance or substances that the person uses” (ref). Page 7; lines 249-252</p>
<p>Providing references for these statements will be helpful.</p>
<p>Efforts to verify references 15 and 17 were unsuccessful.</p>
<p>Response to Review Comments</p>
<p>The response to Reviewer 2’s comment can be reconsidered to improve clarity and flow.</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold>  If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p>For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link></p>
<p>Reviewer #3: No</p>
<p>Reviewer #4: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p><bold>Figure Resubmissions:</bold></p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pmen.0000706.r006">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r006</article-id>
<title-group>
<article-title>Author response to Decision Letter 3</article-title>
</title-group>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj006" link-type="rebutted-decision-letter" object-id="10.1371/journal.pmen.0000706.r005" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>3</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="author-response-date">30 Apr 2026</named-content></p>
<supplementary-material id="pmen.0000706.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.s004" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Response_to_Reviewers_auresp_3.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pmen.0000706.r007" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r007</article-id>
<title-group>
<article-title>Decision Letter 3</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>Ahmed</surname>
<given-names>Gellan Karamallah Ramadan</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Gellan Karamallah Ramadan Ahmed</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="article" id="rel-obj007" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>3</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="letter-date">2 Jun 2026</named-content></p>
<p>PMEN-D-25-00524R3</p>
<p>Alcohol and Substance-Induced Disorder Treatment Cases in Mental Health and Addiction Treatment Facilities from 2013 to 2022: A Descriptive Study</p>
<p>PLOS Mental Health</p>
<p>Dear Dr. Ware,</p>
<p>Thank you for submitting your manuscript to PLOS Mental Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Mental Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Please submit your revised manuscript by Jul 02 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">mentalhealth@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pmen/" xlink:type="simple">https://www.editorialmanager.com/pmen/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<list list-type="bullet">
<list-item>
<p>A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
</list-item>
<list-item>
<p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
</list-item>
<list-item>
<p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
</list-item>
</list>
<p>Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. <italic>Only</italic>  the individual author can complete the verification step; PLOS staff <italic>cannot</italic>  verify ORCID iDs on behalf of authors.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Gellan Karamallah Ramadan Ahmed</p>
<p>Academic Editor</p>
<p>PLOS Mental Health</p>
<p><bold>Journal Requirements:</bold></p>
<p>If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.</p>
<p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
<p><bold>Additional Editor Comments (if provided):</bold></p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><bold>Comments to the Author</bold></p>
<p>Reviewer #3: All comments have been addressed</p>
<p>Reviewer #4: (No Response)</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/criteria-for-publication" xlink:type="simple">publication criteria</ext-link>?&gt;</p>
<p>Reviewer #3: Yes</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>3. Has the statistical analysis been performed appropriately and rigorously?--&gt;?&gt;</p>
<p>Reviewer #3: Yes</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??&gt;</p>
<p>The <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/data-availability" xlink:type="simple">PLOS Data policy</ext-link></p>
<p>Reviewer #3: Yes</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>5. Is the manuscript presented in an intelligible fashion and written in standard English??&gt;</p>
<p>Reviewer #3: Yes</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p><bold>Reviewer #3:</bold>  The manuscript is fair and I think it is good enough for publication.</p>
<p><bold>Reviewer #4:</bold>  Address</p>
<p>Thank you for submitting a revised manuscript. The effort is acknowledged.</p>
<p>Summary</p>
<p>This is a descriptive study that assesses alcohol and substance-induced disorder treatment cases in mental health and addiction treatment facilities in the USA from 2013 to 2022. Secondary data was obtained from the Mental Health Client-Level Data and the Treatment Episode Data Set Admissions. Overall, the study is academically and clinically relevant. However, there are a few concerns.</p>
<p>General comments</p>
<p>• Page numbers and line numbers:</p>
<p>The author could have included page numbers and line numbers of corrected sections for easy review.</p>
<p>• Presentation</p>
<p>There are a number of statements and paragraphs that are not clear at a glance. Example:</p>
<p>“Although this study explores alcohol and substance-induced disorders in both mental health and substance use disorder treatments, limitations must be acknowledged.” Page 9; lines 321-322</p>
<p>This statement can read:</p>
<p>Despite employing robust statistical tools in exploring alcohol and substance-induced disorders in both mental health and substance use disorder treatments, limitations must be acknowledged.</p>
<p>Also, the flow and train of thoughts in some aspects of the introduction, results, discussion, limitations, and conclusion can be difficult to grasp at a glance. The author may consider involving colleagues to help with proofreading. Their suggestions may greatly enhance the flow and clarity of the presentation.</p>
<p>• Long sentences</p>
<p>I commend the effort to rewrite the long sentence cited as an example in the review comment.</p>
<p>“This study also examines mental health diagnoses reported in those receiving mental health treatment and substances used among individuals with an alcohol or substance-induced disorder between 2013 and 2022.” Page 3; lines 106-109</p>
<p>However, the reworded statement (above) could have been presented this way:</p>
<p>“This study also examines mental health diagnoses reported in those receiving mental health treatment. Further, it assesses substances used among individuals with an alcohol or substance-induced disorder between 2013 and 2022.”</p>
<p>Also, there are several long sentences, which are difficult to read. Example:</p>
<p>“One study analyzed the Substance Abuse and Mental Health Services Administration’s Treatment Episode Data Set Admissions [15], reviewing all cases identified as having a “substance-induced disorder” from 1992 to 2022, excluding cases with an “alcohol-induced disorder" unless examining trends of these diagnoses [16].” Page 3; lines 95-99</p>
<p>The statement above can read:</p>
<p>“A study analyzing the Substance Abuse and Mental Health Services Administration’s Treatment Episode Data Set Admissions [15], reviewed all cases identified as having a substance-induced disorder from 1992 to 2022. However, it excluded cases with an alcohol-induced disorder unless examining trends of these diagnoses [16]</p>
<p>“Another limitation is that the mental health treatment data includes diagnoses of mental health disorders, while the substance use disorder treatment data considers substance use as a primary, secondary, or tertiary clinical factor, making it difficult to analyze these aspects consistently across both datasets.”</p>
<p>The statement above can read:</p>
<p>“Another limitation is that the mental health treatment data includes diagnoses of mental health disorders, while the substance use disorder treatment data considers substance use as a primary, secondary, or tertiary clinical factor. This makes it difficult to consistently analyze both datasets.”</p>
<p>These are a few examples of the long sentences. The author was expected to go through the entire manuscript and reword the long sentences to improve the presentation.</p>
<p>Introduction</p>
<p>“Substance-induced disorders are a category of conditions caused by substance use (ref).” Page 3; line 75</p>
<p>“psychosis symptoms” Page 3; line 83</p>
<p>The phrase can read “psychotic symptoms”.</p>
<p>“However, the literature lacks descriptive studies on substance-induced disorder cases within both mental health and substance use treatment settings, alongside clinical characteristics such as substances used and mental health diagnoses.” Page 3; lines 88-91</p>
<p>The statement above is not clear. Please, is the highlighted phrase referring to comorbid mental health disorders? If so, the author should kindly make it clear. This can be done by rewording the statement or breaking the statement into two or three clear sentences.</p>
<p>“Given the unique nature of substance-induced disorders, facilities specializing in treating mental health and/or substance use disorders may encounter individuals with these conditions. However, the literature lacks descriptive studies on substance-induced disorder cases within both mental health and substance use treatment settings, alongside clinical characteristics such as substances used and mental health diagnoses. Descriptive studies are important to the research literature as they can highlight the prevalence of specific conditions and who is affected by them.” Page 3; lines 86-93</p>
<p>I appreciate the effort in trying to link this paragraph to the preceding one. However, I humbly think a different opening statement will help. The facilities were designed to handle such cases, so they are expected to receive such cases.</p>
<p>Materials and Methods</p>
<p>Response is well noted. Thank you.</p>
<p>Results</p>
<p>Response is well noted. The figures added to the reviewer response appear better. Thank you.</p>
<p>Discussion</p>
<p>The presentation (flow and clarity) of the discussion can be improved. For example, the second paragraph of the “Discussion” talks about the prevalence of the reported substances, if I am not mistaken. However, it is very difficult to correlate the long and winding opening statements of the paragraph to the import of the paragraph. Page 7; lines 245-258</p>
<p>Also, I acknowledge the position of the author concerning the lack of data. However, like all other novel studies, the discussion can be done in the light of other national, regional, continental, or global studies.</p>
<p>However, the final decision to accept the “Discussion” in this current format rests with the editor.</p>
<p>Limitation</p>
<p>Response is well noted. Thank you.</p>
<p>Conclusion</p>
<p>The conclusion is long. Page 10</p>
<p>It is expected to be succinct. It is supposed to include a very brief background of the study, key findings, and recommendations or implications for future studies. This can be done in a few sentences. The conclusion is not supposed to be a rehash of the results (with figures).</p>
<p>References</p>
<p>Some of the issues concerning references were missed in the response. Examples:</p>
<p>“Substance-induced disorders are a category of conditions caused by substance use” (ref). Page 3; line 75</p>
<p>“Therefore, managing both the impact of the substance and subsequent mental health symptoms can enhance the care that individuals receive (ref). Variability in the conditions that are induced and the severity of these substance-induced disorders are impacted by the specific substance or substances that the person uses” (ref). Page 7; lines 255-258</p>
<p>Please, providing references for these statements will be helpful.</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold>  If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p>For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link></p>
<p>Reviewer #3: No</p>
<p>Reviewer #4: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p><bold>Figure Resubmissions:</bold></p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pmen.0000706.r008">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r008</article-id>
<title-group>
<article-title>Author response to Decision Letter 4</article-title>
</title-group>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj008" link-type="rebutted-decision-letter" object-id="10.1371/journal.pmen.0000706.r007" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>4</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="author-response-date">10 Jun 2026</named-content></p>
<supplementary-material id="pmen.0000706.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.s005" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Response_to_Reviewers_auresp_4.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pmen.0000706.r009" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r009</article-id>
<title-group>
<article-title>Decision Letter 4</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>Paris</surname>
<given-names>Andreas</given-names>
</name>
<role>Staff Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Andreas Paris</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="article" id="rel-obj009" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>4</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="letter-date">27 Jul 2026</named-content></p>
<p>PMEN-D-25-00524R4</p>
<p>Alcohol and Substance-Induced Disorder Treatment Cases in Mental Health and Addiction Treatment Facilities from 2013 to 2022: A Descriptive Study</p>
<p>PLOS Mental Health</p>
<p>Dear Dr. Ware,</p>
<p>Thank you for submitting your manuscript to PLOS Mental Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Mental Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>The manuscript has been evaluated one reviewer, and their comments are available below.</p>
<p>The reviewer acknowledges that the manuscript has been substantially strengthened and that the principal concerns regarding methodological transparency, global public-health relevance, and interpretation have been satisfactorily addressed.</p>
<p>A small number of issues remain. In particular, references to educational or BMI “differences” should be revised to reflect that the quantitizing procedure identifies descriptive patterns in the distribution of coded content rather than statistically established between-group differences. Claims regarding the international transferability of the findings should also be moderated to distinguish conceptual relevance to wider global policy debates from empirical transferability beyond the specific Finnish study population. Finally, the conclusion should more clearly reflect the balance identified between structural support and individual autonomy and should avoid overstating the extent to which participants’ views align with established effective policies.</p>
<p>Could you please carefully revise the manuscript to address all comments raised?</p>
<p>Please submit your revised manuscript by Aug 26 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">mentalhealth@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pmen/" xlink:type="simple">https://www.editorialmanager.com/pmen/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<list list-type="bullet">
<list-item>
<p>A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
</list-item>
<list-item>
<p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
</list-item>
<list-item>
<p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
</list-item>
</list>
<p>Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. <italic>Only</italic>  the individual author can complete the verification step; PLOS staff <italic>cannot</italic>  verify ORCID iDs on behalf of authors.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Andreas Paris, PhD</p>
<p>Associate Editor</p>
<p>PLOS Mental Health</p>
<p><bold>Journal Requirements:</bold></p>
<p>If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.</p>
<p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
<p><bold>Additional Editor Comments (if provided):</bold></p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><bold>Comments to the Author</bold></p>
<p>Reviewer #4: (No Response)</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/criteria-for-publication" xlink:type="simple">publication criteria</ext-link>?&gt;</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>3. Has the statistical analysis been performed appropriately and rigorously?--&gt;?&gt;</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??&gt;</p>
<p>The <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/data-availability" xlink:type="simple">PLOS Data policy</ext-link></p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p>5. Is the manuscript presented in an intelligible fashion and written in standard English??&gt;</p>
<p>Reviewer #4: Yes</p>
<p>**********</p>
<p><bold>Reviewer #4:</bold>  Address</p>
<p>Thank you for submitting a revised manuscript. The effort is appreciated.</p>
<p>General comments</p>
<p>The comments concerning the long sentences, the structure of the conclusion, and unreferenced statements have been fairly addressed. However, there are a few comments</p>
<p>Introduction</p>
<p>“Given the unique nature of substance-induced disorders, facilities specializing in treating mental health and/or substance use disorders may encounter individuals with these conditions. However, the literature lacks descriptive studies on substance-induced disorder cases within both mental health and substance use treatment settings.” Page 3; lines 86-89</p>
<p>Previous Comment by Reviewer</p>
<p>I appreciate the effort in trying to link this paragraph to the preceding one. However, I humbly think a different opening statement will help. The facilities were designed to handle such cases, so they are expected to receive such cases.</p>
<p>Author’s Response</p>
<p>“Not all mental health or addiction facilities are designed to handle cases with comorbidities, even those that may receive such cases, unfortunately. This opening sentence points to this unfortunate clinical reality.”</p>
<p>Reviewer’s Comment</p>
<p>It appears the author’s response to the comment may be missing some words. It is not clear. However, the statement can be accepted since it does not alter the import of the study.</p>
<p>Discussion</p>
<p>The concerns of the discussion have not been addressed. The final decision to accept the “Discussion” in this current format rests with the editor.</p>
<p>**********</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/mentalhealth/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold>  If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p>For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link></p>
<p>Reviewer #4: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p><bold>Figure Resubmissions:</bold></p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pmen.0000706.r010">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r010</article-id>
<title-group>
<article-title>Author response to Decision Letter 5</article-title>
</title-group>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj010" link-type="rebutted-decision-letter" object-id="10.1371/journal.pmen.0000706.r009" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>5</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="author-response-date">28 Jul 2026</named-content></p>
<supplementary-material id="pmen.0000706.s006" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pmen.0000706.s006" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Response_to_Reviewers_auresp_5.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pmen.0000706.r011" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pmen.0000706.r011</article-id>
<title-group>
<article-title>Decision Letter 5</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>Montague-Cardoso</surname>
<given-names>Karli</given-names>
</name>
<role>Staff Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Karli Montague-Cardoso</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pmen.0000706" document-id-type="doi" document-type="article" id="rel-obj011" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>5</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="letter-date">11 Aug 2026</named-content></p>
<p>Alcohol and Substance-Induced Disorder Treatment Cases in Mental Health and Addiction Treatment Facilities from 2013 to 2022: A Descriptive Study</p>
<p>PMEN-D-25-00524R5</p>
<p>Dear Dr. Ware,</p>
<p>We are pleased to inform you that your manuscript 'Alcohol and Substance-Induced Disorder Treatment Cases in Mental Health and Addiction Treatment Facilities from 2013 to 2022: A Descriptive Study' has been provisionally accepted for publication in PLOS Mental Health.</p>
<p>Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.</p>
<p>Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.</p>
<p>IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.</p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email xlink:type="simple">mentalhealth@plos.org</email>.</p>
<p>Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Mental Health.</p>
<p>Best regards,</p>
<p>Karli Montague-Cardoso</p>
<p>Staff Editor</p>
<p>PLOS Mental Health</p>
<p>***********************************************************</p>
<p>Reviewer Comments (if any, and for reference):</p>
</body>
</sub-article>
</article>